Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Actavis, Cephalon pay-for-delays remain in FTC's bull's-eye

This article was originally published in Scrip

Executive Summary

You've been forewarned, US drug makers. Now more than ever, your reverse-payment settlements remain in the bull's-eye of the Federal Trade Commission (FTC), which is taking sharper aim at the deals with renewed vigor after the US Supreme Court last month declared the agreements subject to antitrust scrutiny.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC022174

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel